Biomedical Center Munich
print

Language Selection

Breadcrumb Navigation


Content

EpiQMAx – a BMC spin-off

Driven by the goal of translating academic findings into clinical applications, EpiQMAx was founded in 2018 by Dr. Moritz Völker-Albert, Dr. Victor Solis und Prof. Dr. Axel Imhof. The BMC spin-off is investigating epigenetic modifications using a platform technology. With this technique, the focus is on the rapid analysis of molecular markers associated with the DNA, which differ even between monozygotic twins. The envisioned fields of application for this technology are diverse. Amongst other projects EpiQMAx works jointy together with the pharmaceutical industry in the development of new diagnostic tools and medication.

Born as an idea during a PhD thesis, EpiQMAx is constantly developing and moved to the IZB on the Campus Martinsried lately. In a magazine article, a TV report and a podcast the founders tell about their vision, the impact of epigenetics and the challenges of starting a company.

Read the article about EpiQMAx in IZB im Dialog under the following link: [link]. The article is on page 32.

Watch the TV report in the broadcast Schwaben und Altbayern (12 January 2020) in the BR Mediathek (in German): [link]

Listen to the podcast Visionäre der Gesundheit with Moritz Völker-Albert under the following link (interview in German): [link]

Please note that the availability of content in media libraries may be only temporary.